|
Gene Therapies & Associated Vectors 2022: Intellectual Property Landscape, Patent Valuation Analysis, Granted Patents and Claims Analysis
Thursday, April 21, 2022
DUBLIN, April 13, 2022 /PRNewswire/ -- The "Gene Therapies & Associated Vectors: Intellectual Property Landscape" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
Although the COVID-19 pandemic limited certain aspects of the wider cell and gene therapies segment of the biopharmaceutical industry, it created significant future opportunities. From the financial perspective, the domain reported strong positive growth, primarily driven by drugs such as ZOLGENSMA, which reported close to 50% year-on-year growth in 2021.
In addition, some innovators, leveraging proprietary technologies, launched COVID-19 directed R&D programs, while others took the opportunity to reposition existing assets in the same direction; either way, industry stakeholders were able to tap into the vast infectious diseases market.
Taking into consideration both historical and recent developments, and modern technological advances, it is evident that this upcoming industry segment is at an inflection point. With the rapidly growing success of genetic medicine prompting more innovators to enter the market, the focus is now on building better and more efficacious assets, based on next generation biotechnology platforms. This is likely to pave the way for a much broader wave of new biological interventions. It is, therefore, important to identify key pockets of innovation and areas of improvement, in order to truly innovate whilst maintaining a competitive edge.
This report summarizes some of the key R&D trends related to gene therapies and affiliated vectors. It also provides a perspective on the pace and focus of innovation in this field, briefly describing the future of gene therapies as mainstream healthcare solutions.
Scope of the Report
The report features an extensive study of some of the key historical and contemporary intellectual property (IP) documents describing gene therapies and affiliated vector constructs. The insights generated in this report have been presented across two deliverables, namely a MS Excel sheet and a MS PowerPoint deck, summarizing the ongoing activity in this domain. Key inclusions are briefly described below:
-- Overall Intellectual Property Landscape: An in-depth review of the
various patents and affiliated IP documents that have been published
related to the diverse technologies, methods, and compositions
associated with the use of genomic data and synthetic DNA / RNA
constructs, for therapeutic purposes. It features insights on both
historical and recent trends in R&D within this niche.
-- Popular / Relevant Prior Art Search Expressions: An examination of IP
literature, shortlisting key words and phrases that have been used to
describe gene therapies and associated vector constructs. The analysis
includes information on the historical use of the aforementioned terms
across different types of IP filings, key affiliated terms, and other
related trends.
-- Patent Valuation Analysis: A competitive benchmarking and valuation
analysis of the IP documents published in this field of innovation,
taking into consideration important parameters, such as type of IP
document, year of application, time to expiry, number of citations and
jurisdiction.
-- Patentability and Freedom to Operate: A systematic approach to identify
relevant areas of innovation by analyzing published IP documents,
defining the uniqueness of patented / patent pending innovations,
understanding the scope of patentability in this domain, and pinpointing
jurisdictions where new and / or modified claims may be filed without
infringing on existing IP.
-- Analysis of Patent Applications: A detailed summary of the patent
applications that were filed across different jurisdictions and their
relative value in the IP ecosystem. The analysis segregates the
intellectual capital in terms of area of innovation and intended
applications, thereby, offering the means to understand key areas of
research and identify innovation-specific IP filing trends.
-- Analysis of Granted Patents: An elaborate summary of the granted patents
across different jurisdictions and their relative value in the IP
ecosystem. The analysis also features a meaningful classification
system, segregating granted patents into relevant categories to help
develop a more detailed perspective on the diverse types of innovations
in this domain and their intended applications, and the feasibility for
innovators to enter into promising product markets.
-- Pockets of Innovation and White Spaces: An insightful analysis of the
various CPC codes used in published IP literature and their affiliated
families, in order to identify historical and existing pockets of
innovation (based on the functional area / industry described by the
elaborate and systematic system of classifying IP); the analysis also
features a discussion on prevalent white spaces in this arena of
research.
-- Claims Analysis: One of the objectives of the report was to analyze and
summarize key inferences from the independent claims mentioned in
granted, active patents in the dataset. Using a systematic segregation
approach, we have analyzed trends associated with [A] the preamble, [B]
type of patent, [C] type of claim and [D] key elements of a claim.
Select Companies Mentioned
-- Abbott
-- Abiomed
-- Acambis
-- Access Biologics
-- ACGT
-- Acuitas Therapeutics
-- Adagene
-- Adaptimmune
-- Adrenas Therapeutics
-- Affymetrix
-- Agenovir
-- Agenta Biotechnologies
-- Agenus
-- Alexion Pharma
-- Alkermes
-- Alpharma
-- AlphaVax
-- Alpine Immune Sciences
-- Alsatech
-- Astellas Pharma
-- AstraZeneca
-- BASF
-- Bavarian Nordic
-- Baxalta
-- Baxter International
-- Canji
-- CanSino Biologics
-- CytoTherapeutics
-- CytRx
-- Dyax
-- EdiGene
-- Editas Medicine
-- Egen
-- Eisai
-- Erytech Pharma
-- Ethicon
-- Etubics
-- Evolva
-- Evotech Biosystems
-- Evox Therapeutics
-- Exemplar
-- Exhaura
-- Exonics Therapeutics
-- Exuma Biotech
-- GeoVax
-- Geron
-- Gilead Sciences
-- Glaxo Smith Kline (GSK)
-- GlobeImmune
-- Goleini
-- Hoechst
-- Homology Medicines
-- ProBioGen
-- Quell Therapeutics
-- RheoGene
-- Ribo Life Science
-- Ribozyme Pharmaceuticals
-- Richland Bio Medical
-- Riken
-- Roche
-- Rocket Pharmaceuticals
-- Rubicon Labs
-- Samyang
-- Sana Biotechnology
-- Sandoz
-- Sangamo Therapeutics
-- Sanofi Pasteur
-- Sarepta Therapeutics
-- Stoke Therapeutics
-- StrideBio
-- Strike Bio
-- Stryker
-- Therion Biologics
-- ToolGen
-- Toppan
-- Transderm
-- TransGenRx
-- UCB Biopharma
-- Ultragenyx
-- Umoja Biopharma
-- Unicyte
-- Valentis
-- Vascular Biogenics
-- Vaxart
-- Vaxbio
-- VaxCell
-- Vecprobio
-- VersiTech
-- Vertex Pharmaceuticals
-- VGX Pharmaceuticals
-- Vycellix
-- Wellstat Biologics
-- Xenetic Biosciences
-- XyloCor Therapeutics
-- Zycos
For more information about this report visit https://www.researchandmarkets.com/r/7ewxxj
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/gene-therapies--associated-vectors-2022-intellectual-property-landscape-patent-valuation-analysis-granted-patents-and-claims-analysis-301524735.html
SOURCE Research and Markets
|
|
|
|
|
|
 |
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Marketing Evolution Announces New Investment Led by Insight Partners to Power AI-Ready Marketing Data for the Agentic Era | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
|
|
